Aligos Therapeutics vs Evogene
Evogene is the larger business, with $3.9m of revenue in fiscal 2025 against $2.2m for Aligos Therapeutics (1.8 times as much). Evogene grew faster (-30.9% against -39.5%). Evogene kept more of each dollar of sales as profit: a net margin of -220.2% against -1106.7%.
| Latest fiscal year | Aligos TherapeuticsALGS, 2025 | EvogeneEVGN, 2025 |
|---|---|---|
| Revenue | $2.2m | $3.9m |
| Revenue growth | -39.5% | -30.9% |
| Net income | −$24.2m | −$8.5m |
| Operating margin | — | -364.2% |
| Net margin | -1106.7% | -220.2% |
| Return on equity | -196.9% | — |
| Free cash flow | −$82.5m | −$13.6m |
| Cash | $18.3m | $13.0m |
| Total debt | $0 | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 82 | — |
| Market value | $29.6m | $3.1m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 3 buys, 0 sales |